Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection by Keiichi Masaki et al.
RESEARCH Open Access
Long-term effects of peginterferon alfa-2a
therapy in Japanese patients with chronic
hepatitis B virus infection
Keiichi Masaki1, Fumitaka Suzuki1*, Tasuku Hara1, Yusuke Kawamura1, Hitomi Sezaki1, Tetsuya Hosaka1,
Norio Akuta1, Masahiro Kobayashi1, Satoshi Saitoh1, Yoshiyuki Suzuki1, Yasuji Arase1, Kenji Ikeda1,
Mariko Kobayashi2 and Hiromitsu Kumada1
Abstract
Background: There is no information on the long-term effects of peginterferon (PEG-IFN) alfa-2a therapy for
chronic hepatitis B (CHB) in Japan. This double-blind, randomized trial investigated the efficacy of PEG-IFN therapy.
Methods: We analyzed 22 Japanese patients with CHB (hepatitis B e antigen [HBeAg]-positive: 17, HBeAg-negative:
5) treated with PEG-IFN alfa-2a and followed-up posttreatment for 5 years. Responders represented patients who
showed persistent normalization of alanine transferase (ALT) levels, HBeAg clearance, and low hepatitis B virus (HBV)
DNA levels (HBeAg-positive patient; <5 log copies/mL, HBeAg-negative patient; <4.3 log copies/mL) at end of
treatment, and at 1, 2, 3, 4 and 5 years posttreatment. In addition, baseline HBeAg-positive patients who showed
sustained normalization of ALT level, HBeAg clearance, and low HBV DNA level for more than 6 months until at 1, 2,
3, 4, and 5 years after completion of PEG-IFN were also classified as “triple responders” and the proportion of triple
responders relative to all patients was termed the “triple response rate”.
Results: The response rates among HBeAg-positive patients were 13 %, 25 %, 14 %, 21 % and 21 % at end of
treatment, and at 1, 2, 3, 4, and 5 years, respectively. The response rate tended to be higher in patients treated for
48 than 24 weeks. The respective response rates among HBeAg-negative patients were 0 %, 20 %, 20 %, 20 % and
25 %. During the treatment period, hepatitis B surface antigen (HBsAg) clearance at 3.5 years was noted in one
patient, who was 37-year-old, male, had genotype C and received PEG-IFN alfa-2a at 90 μg for 48 weeks.
Conclusion: At 5 years after completion of PEG-IFN, the triple response rate in HBeAg-positive patients and
combined response rate in HBeAg-negative patients were 21 % (3/14) and 25 % (1/4), respectively. The triple
response was seen in three patients who had all been treated with PEG-IFN for 48 weeks.
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Background
Hepatitis B virus (HBV) infection is a common disease
that can induce chronic carrier state and is associated
with risk of development of progressive disease and he-
patocellular carcinoma [1]. Interferon (IFN) and several
nucleoside/nucleotide analogues, such as lamivudine,
adefovir dipivoxil, entecavir, and tenofovir disoproxil fu-
marate, are currently approved for the treatment of
chronic hepatitis B (CHB) in several countries [2–8].
These drugs can suppress the activity of hepatitis and
progression of liver fibrosis, thus preventing hepatic fail-
ure and hepatocarcinogenesis and improving quality of
life and survival [9–11]. Successful treatment of CHB
with clearance of hepatitis B e antigen (HBeAg), reduc-
tion in serum HBV DNA levels, and normalization of
alanine transferase (ALT) levels is associated with favor-
able long-term outcome, independent of the antiviral
drug used [12].
However, conventional IFN alfa has suboptimal
pharmacokinetics, and it requires administration three
times a week, resulting in fluctuating drug exposure and
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burden on patients [3, 4]. On the other hand, one of the
problems associated with the use of nucleoside/nucleo-
tide analogues is the low HBeAg seroconversion rate [6,
13]. Furthermore, protracted use of nucleoside/nucleo-
tide analogues, such as lamivudine or adefovir dipivoxil,
can increase the likelihood of drug resistance [4, 5, 14]
and late adverse effects [15].
Peginterferon (PEG-IFN) alfa-2a, prepared by
attaching a large, branched, 40-kD polyethylene glycol
molecule to IFN alfa-2a [16], has better pharmacokin-
etics than the conventional IFN alfa, allowing once-
weekly dosing and maintenance of effective serum
concentrations throughout the dosage interval [17]. A
randomized study of PEG-IFN alfa-2a therapy pub-
lished in 2004 involving 537 HBeAg-negative adult
patients treated for 48 weeks with either PEG-IFN
alfa-2a or lamivudine, or a combination of the two,
reported significantly higher posttreatment response
rates with PEG-IFN alfa-2a compared with lamivudine
alone. Furthermore, ALT normalization at 6 months
posttreatment was noted in 59 % of patients treated
with PEG-IFN alfa-2a, 60 % of patients treated with
the combination of PEG-IFN alfa-2a and lamivudine,
and 44 % of patients treated with lamivudine alone
(P = 0.004, P = 0.003), with 43 %, 44 %, 29 % rates of
HBV DNA levels of ≤20,000 copies/ml at 6 months
posttreatment, respectively (P = 0.007, P = 0.003) [18].
Another randomized study of 814 HBeAg-positive
adult patients treated for 48 weeks with either PEG-
IFN alfa-2a or lamivudine, or their combination pub-
lished in 2004 showed significantly higher posttreat-
ment response rate for PEG-IFN alfa-2a compared
with lamivudine. HBV DNA level was ≤100,000 cop-
ies/ml at 6 months posttreatment in 32 % of patients
treated with PEG-IFN alfa-2a, 34 % of those treated
with the combination of PEG-IFN alfa-2a and lamivu-
dine, and 22 % of those treated with lamivudine alone (P
= 0.012, P = 0.003), with HBeAg seroconversion rates at
6 months posttreatment of 32 %, 27 %, 19 %, respectively
(P < 0.001, P = 0.002) [19].
Another long-term follow-up study of 315 of patients
treated with either PEG-IFN alfa-2a or lamivudine, or
their combination showed a higher rate of ALT
normalization at 3 years posttreatment in patients
treated with PEG-IFN alfa-2a (31 %) than with lami-
vudine alone (18 %, P = 0.032), and HBV DNA levels
of ≤10,000 copies/ml were noted in 28 % and 15 % of
the patients, respectively (P = 0.039). In addition,
8.7 % of those treated with PEG-IFN alfa-2a-
containing regimen showed HBsAg clearance [20].
However, specific data on the long-term effects of
PEG-IFN therapy particularly for Japanese patients are
not available at present. The aim of the present study
was to determine the long-term effects of PEG-IFN alfa-
2a administered for 24 or 48 weeks, at dose of 90 and
180 μg in Japanese patients with CHB.
Methods
Patients
This double-blind, randomized trial included 22 Japanese
patients (6 females and 16 males) who were chronically in-
fected with HBV alone (confirmed HBsAg positivity for at
least six months and negativity for other hepatitis viruses)
and commenced PEG-IFN treatment between September
2007 and December 2008 at the Department of Hepatol-
ogy, Toranomon Hospital (Table 1). Patients were in-
cluded in this study if they aged more than 20 years,
serum HBsAg-positive, HBsAb-negative by screening,
high ALT twice within 180 days of enrolment, and con-
firmed CHB. In HBeAg-positive patients, the following
criteria were also used for inclusion; positivity for DNA
polymerase, with HBV DNA ≥5.7 log copies/ml. The fol-
lowing criteria were also used for inclusion of HBeAg-
negative patients; negativity for HBeAg, with HBV DNA
≥5.0 log copies/ml. All patients were confirmed to have
HBV hepatitis and not other vectors, such as infection
with hepatitis C virus or autoimmune hepatitis. None had
history of drug abuse or alcoholic hepatitis. The exclusion
criteria were neutrophil count <1,500/mm3, platelet count
< 90,000/mm3, hemoglobin concentration <10 g/dL, de-
compensated liver disease, history of organ transplant-
ation, creatinine clearance <50 ml/min, severe psychiatric
disease, diabetes requiring pharmacotherapy, poorly con-
trolled hypertension, malignancy, severe or chronic car-
diac or pulmonary disease, immunologically-mediated





Age, years (range) 33 (22–50)
Previous treatment with interferon 6 (27.2 %)
Previous treatment with nucleoside analog 1 (1.7 %)
Laboratory Data
Aspartate aminotransferase, IU/L (range) 58 (28–237)
Alanine aminotransferase, IU/L (range) 111 (41–397)
Bilirubin, mg/dL (range) 0.7 (0.3-1.6)
Albumin, g/dL (range) 3.9 (3.5-4.4)
Platelets, ×103/μL (range) 196 (106–306)
HBsAg, (IU/ml) 2370 (22.1-75500)
Serum HBV DNA, log copies/mL (range) 7.6 (5.3 to >7.6)
HBeAg, positive/negative 17/5
HBV genotype (A/B/C) 2/2/18
Data are median and (range) or number and (percentage)
HBV hepatitis B virus, HBeAg Hepatitis B e antigen, ND not done
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disease, stroke or retinopathy and previous treatment with
pegylated INF.
The study was conducted in accordance with the eth-
ical principles of the Declaration of Helsinki and was ap-
proved by the Toranomon Hospital Ethical Committee.
Informed consent was obtained from each patient.
Interferon therapy and assessment of response to
therapy
Of the 22 patients included in this study, 17 were
HBeAg-positive and 5 were HBeAg-negative. The 17
HBeAg-positive patients were randomly assigned to re-
ceive PEG-IFN alfa-2a (PEGASYS: Hoffmann-La Roche
Inc., Basel, Switzerland) at either 90 μg for 24 weeks
(n = 4) or 48 weeks (n = 4), 180 μg for 24 weeks (n = 5), or
48 weeks (n = 4). The 5 HBeAg-negative patients were
randomly assigned to receive PEG-IFN alfa-2a at either
90 μg (n = 3) or 180 μg (n = 2) for 48 weeks.
The number of responders was evaluated at the end of
each treatment, and at 0.5, 1, 2, 3, 4, and 5 years after
completion of PEG-IFN alfa-2a. Among the HBeAg-
positive patients at baseline, responders were defined as
patients who showed normalization of serum ALT level
(normal level: 6–30 IU/L), HBeAg clearance, and low
HBV DNA level (<5 log copies/mL) at the end of com-
pletion of PEG-IFN alfa-2a treatment. In addition, base-
line HBeAg-positive patients who showed sustained
normalization of ALT level, HBeAg clearance, and low
HBV DNA level for more than 6 months until each
point at 0.5, 1, 2, 3, 4, and 5 years after completion of
PEG-IFN alfa-2a were also classified as “triple re-
sponders” and the proportion of triple responders rela-
tive to all patients was termed the “triple response rate”.
Among baseline HBeAg-negative patients, responders
were defined as those who showed sustained
normalization of ALT level and low HBV DNA level
(<4.3 log copies/mL) for more than 6 months until each
point after completion of PEG-IFN alfa-2a therapy. In
addition, baseline HBeAg-negative patients who showed
sustained normalization of ALT level and low HBV
DNA level for more than 6 months until each point at
0.5, 1, 2, 3, 4, and 5 years after completion of PEG-IFN
alfa-2a were also classified as “Combined responders”.
All patients not considered responders were labeled as
“non-responders.” Patients who were switched to other
therapies (IFN or nucleoside/nucleotide analogues) after
completion of the study were also considered non-
responders.
Blood tests and serum viral markers
Routine biochemical tests were performed monthly
using standard procedures during treatment and the first
12 months following IFN therapy and at least every
2 months thereafter. Levels of HBsAg, HBeAg, and anti-
HBe were determined using enzyme-linked immuno-
sorbent assay (ELISA) using a commercial kit (HBeAg
EIA; Institute of Immunology, Tokyo) or Chemilumines-
cent Enzyme Immunoassay (CLEIA; Lumipulse System,
Fujirebio, Inc. Tokyo). HBV DNA levels were measured
using COBAS TaqMan HBV Test; v1.0 or v2.0, (Roche
Diagnostics K.K., Tokyo).
HBV genotype
The major genotypes of HBV were determined using
ELISA (Institute of Immunology, Tokyo) or PCR-invader
assay (BML, Inc) according to the method described by
Usuda et al. [21] and Tadokoro et al. [22].
Results
Study population
The majority of patients were male (n = 16, 73 %), and
infected with HBV genotype C (n = 18, 82 %). The base-
line characteristics of the patients are summarized in
Table 1. Although few patients had genotypes A and B,
the distribution of HBV genotype was similar in patients
with CHB who received care in our hospital, with a
follow-up period of more than 2 years [23]. Two of 2 pa-
tients with genotype A, 1 of 2 with genotype B, 14 of 18
with genotype C were HBeAg-positive at the commence-
ment of treatment. At 5 years after completion of PEG-
IFN, 11 patients in HBeAg-positive case, and 4 patients
in HBeAg-negative case were switched to other treat-
ments. Three HBeAg-positive patients did not complete
the follow-up. Eleven patients of the HBeAg-positive
group were switched to another treatment (5 patients:
entecavir, 6 patients: conventional IFN alfa therapy) from
one to four years after PEG-IFN alfa-2a. Four patients of
the HBeAg-negative group were switched to another
treatment (2 patients: entecavir, 2 patients: conventional
IFN alfa therapy) from one to two years after PEG-IFN
alfa-2a. Adverse events, such as diarrhea and neutro-
penia, were noted in some of the patients, but there
were no serious adverse events that required cessation of
treatment and all patients completed the study without
discontinuation of the allocated therapy.
Response of HBeAg-positive patients to PEG-IFN alfa-2a
therapy
ALT normalization among HBeAg-positive patients was
noted in 12 % (2/17), 29 % (5/17), 19 % (3/16), 31 % (5/
16), 21 % (3/14), 21 %(3/14) and 21 % (3/14) at the end
of treatment, and at 0.5, 1, 2, 3, 4, and 5 years after com-
pletion of PEG-IFN alfa-2a, respectively. The rate of
HBeAg seroconversion was 24 % (4/17), 24 % (4/17),
25 % (4/16), 25 % (4/16), 21 % (3/14), 21 % (3/14) and
21 % (3/14), respectively. The rate of low HBV level
(<5 log copies/mL) was 41 % (7/17), 18 % (3/17),
19 % (3/16), 31 % (5/16), 21 % (3/14), 21 % (3/14)
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and 21 % (3/14), respectively (Table 2). The triple re-
sponse rate was 6 % (1/17), 6 % (1/17), 13 % (2/16),
25 % (4/16), 14 % (2/14), 21 % (3/14) and 21 % (3/14), re-
spectively. Among the patients who achieved the triple re-
sponse at 2 years, one patient did not complete the
follow-up and another patient had ALT rebound (up to
32 IU/L). Two of 3 patients who achieved triple response
at 5 years after completion of PEG-IFN were genotype C
and the other was genotype A. At more than 2 years after
completion of PEG-IFN alfa-2a, the rates of ALT
normalization, HBeAg seroconversion, low HBV level (<5
log copies/mL), and triple response rate tended to be
higher in patients treated for 48 weeks with PEG-IFN alfa-
2a than 24 weeks. The three patients who achieved triple
response were young (range, 26–34 years), had high titer
of ALT, low titer of HBeAg, and received PEG-IFN alfa-2a
treatment for 48 weeks (Table 3).
Response of HBeAg-negative patients to PEG-IFN alfa-2a
therapy
ALT normalization among HBeAg-negative patients was
noted in 40 % (2/5), 60 % (3/5), 60 % (3/6), 20 % (1/5),
20 % (1/5), 20 % (1/5) and 25 % (1/4) at the end of treat-
ment, and at 0.5, 1, 2, 3, 4, and 5 years after completion
of PEG-IFN alfa-2a, respectively. Furthermore, the re-
spective rates of low HBV level (<4.3 log copies/mL)
were 80 % (4/5), 20 % (1/5), 0 % (0/5), 20 % (1/5), 20 %
(1/5), 20 % (1/5) and 25 % (1/4) (Table 4). The combined
response rate was 40 % (2/5), 20 % (1/5), 0 % (0/5), 20 %
(1/5), 20 % (1/5), 20 % (1/5), and 25 % (1/4), respectively.
The single patient who achieved combined response at
3 years after completion of PEG-IFN was genotype C.
Only one patient who received PEG-IFN alfa-2a at 90 μg
for 48 weeks achieved ALT normalization and low HBV
level (<4.3 log copies/mL) at more than 2 years after
completion of PEG-IFN.
HBsAg seroclearance
At 3.5 years, HBsAg clearance occurred in one male pa-
tient who was 37 years old, had genotype C and was
treated with PEG-IFN alfa-2a at 90 μg for 48 weeks. In
this patient, ALT and HBV-DNA levels decreased during
the treatment period (ALT: from 182 at baseline to
38 IU/ml, HBV-DNA: from 6.6 to 4.1 log copies/ml, re-
spectively). However, their levels gradually increased
from the end of treatment to 8 weeks posttreatment
(ALT: from 38 to 209 IU/ml, HBV-DNA: from 4.1 to 5.9
log copies/ml), but then decreased again up to 5 years
(ALT: 20 IU/ml, HBV-DNA: <1.5 log copies/ml) [Fig. 1].
None of the other patients showed HBsAg
seroclearance.
ALT levels during follow-up
We defined ALT rebound as elevation of ALT level at
posttreatment to ≥100 IU/ml than the nadir. Figure 2a
and b show ALT levels during and after PEG-IFN alfa-2a
treatment with and without ALT rebound. Among the
17 HBeAg-positive patients, 10 showed ALT rebound,
while 3 of the 5 (60 %) HBeAg-negative patients showed
ALT rebound. Among these 10 patients, one of six
(17 %) patients who received PEG-IFN alfa-2a for
24 weeks, achieved HBeAg seroconversion and had per-
sistently low HBV DNA level (<5 log copies/mL). Two
of 4 (50 %) patients who received PEG-IFN alfa-2a for
48 weeks achieved HBeAg seroconversion and had per-
sistently low HBV levels (<5 log copies/mL). On the
other hand, among HBeAg-positive patients who did not
show ALT rebound, one of 2 patients who received
PEG-IFN alfa-2a for 24 weeks had persistently low HBV
level (<5 log copies/mL), and two of the 5 (40 %) pa-
tients who received PEG-IFN alfa-2a for 48 weeks
achieved HBeAg seroconversion and had persistently
low HBV levels (<5 log copies/mL). The baseline ALT
levels of the patients who did not show ALT rebound
and achieved HBeAg seroconversion were higher than
200 IU/L. Among the HBeAg-negative patients, 3 of
the 5 patients showed ALT rebound and had low
HBV DNA levels.
Clinical course
The clinical course is illustrated in Fig. 3. Among the 17
HBeAg-positive patients, 5 achieved HBeAg seroconversion
Table 2 Response of HBeAg-positive patients to various doses




EOT Time after end of treatment (years)
0.5 1 2 3 4 5
90 μg / 24 week
ALT normalization 1/4 0/4 0/4 0/4 0/4 0/4 0/4
HBeAg seroconversion 0/4 0/4 0/4 0/4 0/4 0/4 0/4
Low HBV (<5 log copies/mL) 0/4 0/4 0/4 0/4 0/4 0/4 0/4
180 μg / 24 week
ALT normalization 0/4 0/4 0/4 1/4 0/3 0/3 0/3
HBeAg seroconversion 0/4 0/4 1/4 1/4 0/3 0/3 0/3
Low HBV (<5 log copies/mL) 2/4 0/4 1/4 2/4 0/3 0/3 0/3
90 μg/48 week
ALT normalization 0/4 2/4 1/3 2/3 1/3 2/3 2/3
HBeAg seroconversion 1/4 1/4 1/3 2/3 2/3 2/3 2/3
Low HBV (<5 log copies/mL) 1/4 2/4 1/3 2/3 2/3 2/3 2/3
180 μg/48 week
ALT normalization 1/5 3/5 2/5 2/5 2/4 1/4 1/4
HBeAg seroconversion 3/5 3/5 2/5 1/5 1/4 1/4 1/4
Low HBV (<5 log copies/mL) 4/5 1/5 1/5 1/5 1/4 1/4 1/4
EOT end of treatment
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(3 patients during treatment and 2 posttreatment; 1 at
1 year posttreatment and 1 at 2 year posttreatment). Three
of the 5 HBeAg seroconverted patients achieved triple re-
sponse. Among the 12 patients who did not achieve HBeAg
seroconversion, 11 were switched to another treatment (5
patients: entecavir, 6 patients: conventional IFN alfa ther-
apy). Specifically, of the 4 patients who were treated with
PEG-IFN alfa-2a at 90 μg for 24 weeks, 1 and 3 were
switched to entecavir and conventional IFN, respectively.
Furthermore, among the 3 patients who received PEG-IFN
alfa-2a at 180 μg for 24 weeks, 1 and 2 were switched to
entecavir and conventional IFN, respectively. The single pa-
tient who received PEG-IFN alfa-2a at 90 μg for 48 weeks
was switched to conventional IFN and the 3 patients who
received PEG-IFN alfa-2a at 180 μg for 48 weeks were
switched to entecavir. Among them, HBeAg seroconversion
was noted in 4 of the 5 patients who were treated with
entecavir and 3 of 6 patients who received IFN therapy.
Among HBeAg-negative patients, 4 of 5 patients were
switched to another treatment; entecavir (n = 2), conven-
tional IFN alfa therapy (n = 2). Furthermore, those who re-
ceived PEG-IFN alfa-2a at 90 μg for 48 weeks, 2 were
switched to entecavir and 2 to conventional IFN. The two
patients who received PEG-IFN alfa-2a at 180 μg for
48 weeks were switched to entecavir (n = 1) and conven-
tional IFN (n = 1). All patients who were switched to NAs
treatment had low HBV levels (under the measurement
range) during treatment with nucleoside analogs (NA).
Discussion
The goal of antiviral therapy in CHB is to prevent liver
failure and hepatocarcinogenesis by suppressing the ac-
tivity of hepatitis, progression of liver fibrosis, and
improvement of life expectancy and quality of life. The
long-term goal of this therapy is elimination of HBsAg.
On the other hand, the short-term goals of antiviral
treatment are persistent normalization of ALT, HBeAg
negativity, and suppression of HBV-DNA replication.
PEG-IFN alfa-2a, like conventional IFN alfa, has a dual
immunomodulatory and antiviral modes of action. In
Japan, since 1988, 4-week treatment with IFN is fully
covered by the Government-based universal healthcare
system. Furthermore, since 2002, 24-week treatment,
and since 2011, 48-week PEG-IFN treatment were intro-
duced. One randomized study [24] reported an increase
in triple response (HBeAg seroconversion, HBV DNA
<5 log copies/ml and ALT normalization) rate at
24 weeks post-treatment in HBeAg-positive patients,
and that such response correlated with the dose and
duration of treatment (PEG-IFN alfa-2a at 90 μg for
24 weeks: 4.9 %, PEG-IFN alfa-2a at 180 μg for 24 weeks:
9.8 %, PEG-IFN alfa-2a at 90 μg for 48 weeks: 17.1 %,
PEG-IFN alfa-2a at 180 μg for 48 weeks:19.5 %). Among
HBeAg-negative patients, treatment with PEG-IFN alfa-
2a at 90 μg and 180 μg for 48 weeks resulted in 37.5 %
and 37.9 % HBV DNA suppression (<4.3 log copies/ml
at 24 weeks posttreatment), respectively. However, there
are no data on the long-term response to PEG-IFN alfa-
2a treatment in Japanese patients with CHB, and thus
the present study is the first that documents the
long-term outcome of treatment with PEG-IFN alfa-
2a in Japanese patients with CHB.
We reported in a previous study that HBeAg, HBV-
DNA level, age, sex, IFN pretreatment, duration of treat-
ment, and levels of albumin and aspartate transaminase
(AST) were important determinants of the long-term
Table 3 Clinical features of three patients who achieved triple response










1 26/male C 7.6 4470 positive 180 48 47/123
2 30/female C 5.3 1000 positive 90 48 45/62
3 34/male A 7.6 881 positive 90 48 37/397
Table 4 Response of HBeAg-negative patients to various doses and duration of PEG-IFN alfa-2a therapy analyzed according to
endpoint
Dose/duration and endpoint EOT Time after end of treatment (years)
0.5 1 2 3 4 5
90 μg/48 week
ALT normalization 1/3 1/3 1/3 1/3 1/3 1/3 1/2
Low HBV (<4.3 log copies/mL) 2/3 1/3 0/3 1/3 1/3 1/3 1/2
180 μg/48 week
ALT normalization 1/2 2/2 2/2 0/2 0/2 0/2 0/2
Low HBV (<4.3 log copies/mL) 2/2 0/2 0/2 0/2 0/2 0/2 0/2
EOT end of treatment


























EOT: End of treatment
HBV DNA
ALT










HBsAg (IU/ml 1310 530 236 81.8 13.2 1.01 0.05 0.02 0.01
































































Fig. 2 ALT levels of individual patients from pretreatment to end of treatment, and at 0.5, 1, 2, 3, 4 and 5 years after completion of treatment
according to the duration of PEG-IFN treatment a with ALT levels rebound, b without ALT levels rebound. EOT: End of treatment
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response to IFN, and that non-C genotype was an im-
portant factor in HBeAg-positive patients [2]. In the
NEPTUNE study, Liaw et al. [25] reported that treat-
ment with PEG-IFN alfa-2a at 180 μg for 48 weeks was
the most efficacious and beneficial treatment regimen
for HBeAg-positive patients predominantly infected with
genotypes B or C, compared with lower doses and
shorter durations. Following that study, PEG-IFN alfa-2a
at 180 μg for 48 weeks became the standard method of
treatment for CHB in Europe and the US [9, 26]. Previ-
ous studies also reported that older age [27, 28], female
sex [27], high titer of ALT [24], low HBV-DNA levels
[19, 25, 27, 28], HBsAg [25], genotype A (compared to
genotype D) [27, 28], and IL28B (major) [28] also influ-
enced the response to PEG-IFN alfa-2a therapy in
HBeAg-positive patients. Furthermore, younger age [29],
female sex [29], high titer of ALT [20, 29], low HBV-
DNA levels [29], genotypes B or C (compared to geno-
type D) [29] influenced the response to PEG-IFN ther-
apy in HBeAg-negative patients. In the present study,
triple response was noted in three HBeAg-positive pa-
tients treated for 48 weeks. These patients were young
(range 26–34 years), had high titers of ALT, low titers of
HBeAg, and received PEG-IFN alfa-2a treatment for
48 weeks. These findings are similar to those reported in
the above previous studies, although there were no
dose-related differences. Further, in the present study,
two of 3 patients were males, which was different from
the above previous studies. The reason for the different
finding was considered the small sample size, especially
only one female received PEG-IFN alfa-2a treatment for
48 weeks.
Marcellin et al. [17] reported that persistently low level
of HBV-DNA is associated with HBsAg clearance during
the posttreatment period. In the present study, 3 of 14
(21 %) HBeAg-positive patients achieved low HBV levels
(<5 log copies/mL) at 5 years after completion of PEG-
IFN, and could potentially show HBsAg clearance.
HBsAg clearance was observed in one HBeAg-negative
patient treated with PEG-IFN alfa-2a at 90 μg for
48 weeks. HBV-DNA levels in this patient decreased
during the treatment period, and gradually decreased
after the rebound up to 5 years. In this patient, the low
HBV-DNA level and HBsAg clearance during the post-
treatment period were considered to be due to the sus-
tained long-term effects of PEG-IFN alfa-2a. We defined
ALT rebound at posttreatment as elevated ALT to
≥100 IU/ml than the nadir. We examined ALT levels in
patients with [Fig. 2a] and without [Fig. 2b] rebound for
each dose and treatment duration. ALT flares during
IFN therapy were reported to be associated with high
virological response [30]. In the present study, HBeAg-
positive patients with ALT rebound achieved higher rate
of HBeAg seroconversion and low HBV levels (<5 log
copies/mL) among those treated with PEG-IFN alfa-2a
for 48 weeks compared to those who were treated for
24 weeks. This finding was considered to be due to
changes in host immune response to HBV resulting
from the immunomodulating effects of PEG-IFN.
PEG-IFN therapy for a finite duration may provide
drug-free, long lasting HBeAg seroconversion, and also
HBsAg negative status. Therefore, PEG-IFN monother-
apy is recommended as the first choice treatment for
CHB by not only the Japanese Society of Hepatology
(JSH) but also the European Association for the Study of
the Liver (EASL) [9], and the American Association for
the Study of Liver Diseases (AASLD) [26]. In the present
study, the triple response rate was 21 % (3/14) at 5 years
after completion of PEG-IFN in HBeAg-positive pa-
tients. This rate is identical to that reported by our
group in another study of HBeAg-positive patients [21 %
(53/247)] at 5 years after the completion of treatment
17 HBeAg-positive patients treated  
with PEG-IFN alfa-2a 
90 or 180 µg for 24 or 48 week 
11 patients
• 5 switched to ETV treatment; and
4 HBeAg seroconverted. 












• 3 achieved triple response.
• 2 were lost to follow-up.
5 HBeAg-negative patients treated 
PEG-IFN alfa-2a 






*2 switched to ETV. 
*2 switched to IFN.
Fig. 3 Schematic diagram of the clinical course of study participants including HBeAg-positive and HBe-negative patients
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with conventional IFN [2]. Further studies of larger
group of patients and longer posttreatment follow-up
period are needed.
On the other hand, treatment with NA is effective in
patients at high risk of progression to liver fibrosis and
cirrhosis. We have determined the antiviral potency after
4 years of continuous entecavir treatment in patients
with CHB infection, and reported that incremental in-
creases were observed in the rates of undetectable HBV-
DNA, HBeAg seroconversion, and ALT normalization,
reaching 96 %, 38 %, and 93 %, respectively, by 4 years
[7]. These rates are higher than those achieved after
PEG-IFN treatment, but in general, the HBsAg negative
rate is lower than that after PEG-IFN, only 0.2 %-5.1 %
after 1–5 years of treatment [31, 32]. On the other hand,
in our previous study, we reported that previous IFN
therapy provided prior to NA therapy, was associated
with HBsAg clearance in HBeAg-positive patients
(HBsAg clearance rate ratio (95 % CI); 6.15 (1.69-22.4),
p = 0.006 by multivariate analysis) [33]. In that study,
HBsAg clearance was more likely to occur in patients
with high baseline ALT levels. Considered together, the
results of our previous and present studies suggest that
introduction of PEG-IFN therapy before NA therapy
could be effective.
Our study had one major limitation related to the
small sample size. However, the study was unique in that
all participating patients completed the 24 and 48 weeks
PEG-IFN alfa-2a treatment without discontinuation. An-
other advantage of the study was it provided the first
documentation of the long-term outcome after treat-
ment with PEG-IFN alfa-2a in patients with CHB in
Japan. Another study of larger patient sample is needed
to validate our findings.
Conclusion
In conclusion, we investigated the long-term effects of
PEG-IFN alfa-2a therapy in Japanese patients. At 5 years
after completion of such therapy, the triple response rate
in HBeAg-positive patients and combined response rate
in HBeAg-negative patients were 21 % (3/14) and 25 %
(1/4), respectively. The triple response was noted in all
three patients treated with PEG-IFN alfa-2a for 48 weeks.
Further studies of larger sample size, longer duration of
treatment (>1 year) and longer follow-up, are warranted
in order to confirm the present findings and establish
the true response to PEG-IFN alfa-2a therapy in Japan.
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